Moderna Inc. has announced a promising collaboration with German biotechnology company Immatics NV in a multiyear partnership aimed at the development of innovative cancer therapies. The collaboration entails a comprehensive agreement, with Moderna agreeing to pay Immatics up to $1.8 billion, including a $120 million upfront payment and up to $1.7 billion if certain milestones are achieved.
The partnership will focus on leveraging the power of messenger RNA (mRNA) technology, among others, to create various cancer-fighting products. These products include mRNA-based antibodies, cancer vaccines, and cell therapy treatments. It is important to note that most of these therapies are still in the early stages of development and have yet to undergo human testing.
While Moderna has gained significant recognition for its rapid success in developing highly effective COVID-19 mRNA vaccines, the company has been actively exploring other potential applications for its mRNA technology. Cancer treatment has emerged as a particularly promising area, and Moderna is already collaborating with Merck & Co. on a personalized cancer vaccine targeted at melanoma and other tumors. However, the testing and development process for these cancer therapies could still take several years to complete.
The collaboration with Immatics presents exciting opportunities for Moderna to further diversify and expand the applications of its mRNA-based assets. Under the partnership, Moderna will develop an mRNA-based vaccine to augment Immatics' anti-cancer cell therapy, known as IMA203, which is currently undergoing early human testing. Immatics will lead the early-stage trials if they proceed.
Additionally, Moderna will take the lead in clinical development and sales of other cancer vaccines and mRNA-based treatments resulting from the collaboration. This includes utilizing Immatics' tumor tissue database to develop mRNA vaccines targeting new cancer targets and leveraging mRNA technology to stimulate the production of cancer-fighting antibodies within the body.
By entering this collaboration, both Moderna and Immatics aim to accelerate the development of novel oncology therapies and make significant advancements towards addressing the unmet medical needs of cancer patients. The partnership holds the potential to revolutionize cancer treatment and improve patient outcomes.
While Moderna's COVID-19 vaccine sales may dwindle due to pandemic fatigue, the company is determined to demonstrate the versatility of its mRNA technology in treating other diseases. Through collaborations such as the one with Immatics, as well as its ongoing partnership with Carisma Therapeutics Inc. for cancer cell therapies, Moderna is actively diversifying its product portfolio. Additionally, the company is eagerly awaiting clinical trial data for its mRNA-based flu shot, which it hopes to combine with its COVID-19 vaccine, further expanding its therapeutic reach.
In light of this collaboration, Moderna's shares have experienced a decline of 40% since the start of the year, highlighting the need for the company to showcase its potential beyond COVID-19 vaccines and regain investor confidence.